HBV Core Particles Allow the Insertion and Surface Exposure of the Entire Potentially Protective Region of Puumala Hantavirus Nucleocapsid Protein

Abstract Core particles of the hepatitis B virus (HBV) potentiate the immune response against foreign epitopes presented on their surface. Potential insertion sites in the monomeric subunit of the HBV core protein were previously identified at the N- and C-terminus and in the immunodominant c/e1 region. In a C-terminally truncated core protein these sites were used to introduce the entire 120 amino acid (aa)-long potentially immunoprotective region of the hantavirus (serotype Puumala) nucleocapsid protein. The N- and C-terminal fusion products were unable to form core-like particles in detectable amounts. However, a suppressable stop codon located between the HBV core and the C-terminally fused hantavirus sequence restored the ability to form particles (‘mosaic particles’); in contrast to the C-terminal fusion product the mosaic construct allowed the formation of particles built up by the core protein itself and the HBV core-Puumala nucleocapsid- readthrough protein. The mosaic particles exposed the 120 aa region of the PUU nucleocapsid protein on their surface as demonstrated by ELISA and immuno electron microscopy applying different monoclonal antibodies. Insertion of the hantaviral sequence into the c/e1 region not only allowed the formation of chimeric particles, but again the surface accessibility of the sequence. HBV core antigenicity itself was, however, reduced in the particles carrying insertions in the c/e1 region, probably due to a masking effect of the 120 aa long insert.

[1]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[2]  D. Krüger,et al.  New chimaeric hepatitis B virus core particles carrying hantavirus (serotype Puumala) epitopes: immunogenicity and protection against virus challenge. , 1999, Journal of biotechnology.

[3]  D. Krüger,et al.  Characterization of Potential Insertion Sites in the Core Antigen of Hepatitis B Virus by the Use of a Short-Sized Model Epitope1 , 1999, Intervirology.

[4]  D. Krüger,et al.  Mosaic hepatitis B virus core particles allow insertion of extended foreign protein segments. , 1997, The Journal of general virology.

[5]  B. Hjelle,et al.  Hantaviruses: a global disease problem. , 1997, Emerging infectious diseases.

[6]  A. Vaheri,et al.  Characterization of Puumala virus nucleocapsid protein: identification of B-cell epitopes and domains involved in protective immunity. , 1996, Virology.

[7]  H. Lehvaslaiho,et al.  Human B‐cell epitopes of puumala virus nucleocapsid protein, the major antigen in early serological response , 1995, Journal of medical virology.

[8]  B. Hjelle,et al.  Antibody responses to Four Corners hantavirus infections in the deer mouse (Peromyscus maniculatus): identification of an immunodominant region of the viral nucleocapsid protein , 1995, Journal of virology.

[9]  R. Wirtz,et al.  Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes , 1994, The Journal of experimental medicine.

[10]  C. Schmaljohn Prospects for vaccines to control viruses in the family Bunyaviridae , 1994 .

[11]  P. Pumpens,et al.  Identification of hepatitis B virus core protein regions exposed or internalized at the surface of HBcAg particles by scanning with monoclonal antibodies. , 1994, Virology.

[12]  F. Minion,et al.  Enhanced readthrough of opal (UGA) stop codons and production of Mycoplasma pneumoniae P1 epitopes in Escherichia coli. , 1993, Gene.

[13]  P. Pumpens,et al.  Hybrid hepatitis B virus nucleocapsid bearing an immunodominant region from hepatitis B virus surface antigen , 1993, Journal of virology.

[14]  G. Darai,et al.  A novel mu-capture enzyme-linked immunosorbent assay based on recombinant proteins for sensitive and specific diagnosis of hemorrhagic fever with renal syndrome , 1993, Journal of clinical microbiology.

[15]  Å. Lundkvist,et al.  Antigenic variation of European haemorrhagic fever with renal syndrome virus strains characterized using bank vole monoclonal antibodies. , 1991, The Journal of general virology.

[16]  B. Clarke,et al.  Foreign epitopes in immunodominant regions of hepatitis B core particles are highly immunogenic and conformationally restricted. , 1991, Vaccine.

[17]  J. Dalrymple,et al.  Antigenic subunits of Hantaan virus expressed by baculovirus and vaccinia virus recombinants , 1990, Journal of virology.

[18]  B. Clarke,et al.  Expression in Yeast of Amino-Terminal Peptide Fusions to Hepatitis B Core Antigen and Their Immunological Properties , 1990, Bio/Technology.

[19]  L. Zentilin,et al.  A recombinant hepatitis B core antigen polypeptide with the protamine-like domain deleted self-assembles into capsid particles but fails to bind nucleic acids , 1989, Journal of virology.

[20]  H. Gelderblom,et al.  The structure of group II adenoviruses. , 1967, The Journal of general virology.

[21]  D. Krüger,et al.  Core particles of hepatitis B virus as carrier for foreign epitopes. , 1998, Advances in virus research.

[22]  D. Krüger,et al.  Chimaeric HBV core particles carrying a defined segment of Puumala hantavirus nucleocapsid protein evoke protective immunity in an animal model. , 1998, Vaccine.

[23]  P. Pumpens,et al.  Spatial structure and insertion capacity of immunodominant region of hepatitis B core antigen. , 1996, Intervirology.

[24]  L. Bell-Sakyi,et al.  Theileria annulata sporozoite antigen fused to hepatitis B core antigen used in a vaccination trial. , 1995, Vaccine.

[25]  R. Crowther,et al.  Hepatitis B virus core particles as epitope carriers. , 1995, Intervirology.

[26]  F. Schödel,et al.  Hepatitis B virus core particles as a vaccine carrier moiety. , 1994, International reviews of immunology.

[27]  A. von Brunn,et al.  Principal neutralizing domain of HIV-1 is highly immunogenic when expressed on the surface of hepatitis B core particles. , 1993, Vaccine.

[28]  F. Schödel Prospects for oral vaccination using recombinant bacteria expressing viral epitopes. , 1992, Advances in virus research.

[29]  J. Playfair Immunity to malaria. , 1982, British medical bulletin.